| INTRODUCTION
Cardiovascular disease (CVD) is a leading contributor to disease burden in Africa accounting for nearly a half of the mortality due to non-communicable disease in the region. 1 High blood pressure (BP) is the principal risk factor for CVD. An increasing prevalence of hypertension (HTN) has been documented in Africa; however, detection and treatment rates have been dismal. 2 In Uganda, for example, more than a quarter of the population have documented HTN but less than 15% of all those treated achieve target BP control. 3, 4 As a result, high BP-related CVD morbidity and mortality occurs at a much younger age in Africa compared to the rest of the world. [5] [6] [7] Blood pressure (BP) is a heritable trait with an estimated 39%-50% variation attributed to genetics. 8 Further evidence is derived from several twin and family studies, wherein greater correlation has been noted between monozygotic twins compared with dizygotic twins and greater resemblance of blood measurements documented within families than between families. 9, 10 HTN is 3.8 times more frequent among persons with a positive family history of HTN before the age of 55 years. 11 In native West Africans, heritability for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) is estimated at 45%. 12 Epidemiological studies in subSaharan Africa (SSA) have also been unanimous in their findings of a strong association between family history of HTN and its incidence. 13 Sub-Saharan populations are disproportionately affected by HTN.
Numerous prevalence studies have documented higher prevalence and poorer control of HTN in the East and Southern African regions than the North African region. 2, 14 Differences in environment risks, while important, may not completely explain the disparity in prevalence of HTN and its control across SSA. 15 The other mechanisms responsible for these differences include variation in genetic predisposition as a result of varying frequencies of common disease susceptibility patterns or the presence of population-specific alleles especially in populations with a high level of genetic heterogeneity such as those of SSA [16] [17] [18] and these need to be further examined. 
| MATERIALS AND METHODS
The methods of the MEPI-CVD survey have been described in detail elsewhere. 3, 24 The MEPI-CVD survey was a cross-sectional study con- with the subjects putting on loose clothing. The waist circumference was measured to the nearest 0.1 cm at the level of the midpoint between the inferior margin of the last rib and the crest of the ilium in the midaxillary plane using a non-stretchable tape measure.
| Candidate single nucleotide polymorphism selection
Thirty single nucleotide polymorphisms (SNPs) were selected for genotyping and association analysis with BP. These SNPs were selected based on the previous association evidence with BP from GWASs or admixture mapping analysis 23, [25] [26] [27] [28] [29] (Table S1 , Supporting Information).
| DNA genotyping and quality control
Complete phenotype information was obtained in 2881 participants.
Genomic DNA was extracted from whole blood drawn from these participants using Gentra Puregene kits (Qiagen GmbH, Hilden, Germany).
Genotyping was performed using the PlexSeq process (Plexseq Diagnostics, Cleveland, Ohio). Primers were designed to amplify regions surrounding each SNP using a multiplexed approach. Each primer design included additional sequence at the 5 0 end that was then used to anneal universal barcoded Illumina primers in a secondary amplification reaction. All samples (including negative and positive controls)
were uniquely barcoded and sequenced simultaneously using a MiSeq instrument (Illumina, San Diego, California). Fastq files were analyzed using Plexcall software (PlexSeq Diagnostics, Cleveland, Ohio) which provides genotype calls for all SNP's in each sample.
SNP genotyping quality was evaluated for departures from
Hardy-Weinberg equilibrium (HWE) and call rate. One SNP had significant departure from the HWE with P ≤ .001 and was excluded from analysis. Two SNPs with a missing rate larger than 90% were also excluded from analysis. Two hundred and fourteen samples with genotype call rate less than 85% were excluded from the analysis.
After quality control analyses (QCs), 27 SNPs and 2667 individuals were left for further association analysis.
| Association analysis
All data management was carried out using R. 30 Genotype and phenotype association analysis was carried out using software PLINK. 3 | RESULTS
| Baseline population characteristics
The prevalence of HTN among the MEPI-CVD study was 1237 of 5183 (24%). Among the study participants, 782 cases and 2099 controls were selected for genotyping. 
| Association analysis among Ugandan samples with 4 BP traits
Thirty SNPs which are known to be associated with BP or HTN were genotyped (Table S1 ). Three of them failed QCs and were therefore were not further included for analysis. Table 2 lists the 11 SNPs that were significantly associated with at least 1 BP trait (P < .05). To control for the effects of multiple testing, we used Li and Ji's approach which assumes that correlated tests are independent and adjusts them according to an "effective number" (M eff ) of independent tests. 34 These M eff based tests have been shown to control error rate accurately, resulting in an increase in power. We estimated 56 independent tests for the 27 SNPs and the 4 BP traits.
Under null hypothesis that none of 56 independent tests were significant, we expected 56 × 0.05 = 2.7, around 3 SNPs with P < .05.
We observed 11 significant SNPs, which are substantially higher than expected.
Among the significant SNPs, 4 SNPs were associated with SBP:
rs2004776, rs7726475, rs11837544 and rs2681492 and the nearest genes are AGT, NPR3/SUB1, PLXNC1 and ATP2B1, respectively. Six SNPS; rs2004776, rs11977526, rs11191548, rs381815, rs2681492 and rs1327235 and the nearest genes are AGT, IGFBP3, CYP17A1, PLEKHA7, ATP2B1 and JAG, respectively, were associated with DBP.
Two SNPs located within AGT and IGFBP-3 genes, respectively, were associated with HTN. For PP, 4 variants rs1458038, rs11725861, rs7726475 and rs11953630 whose corresponding genes are FGF5, CHIC2, SUB1/NPR3 and EBF1 reached significance (P < .05). As combining evidence of the 4 BP traits improves the power of association evidence, we performed CPASSOC analysis. 32 Eight of the 11 variants were significantly associated with all the BP traits (Table 2) .
We next calculated a risk score for each individual by P β i g i , where β i and g i are the effect size and genotype value of the ith variant of the 27 variants we selected and tested the association between the risk score and each of BP traits. The effect size β i was obtained from the published data (Table S1 ). Significant linear regression association evidence was observed for SBP (effect size = 0.64, P = .0026), DBP (effect size = 0.45, P = .0214). However, there was no significant association for HTN (effect size = 1.28, P = .089). We further compared the effect sizes estimated from this study and that from the published data (Table S1 ) and observed that the effect sizes were highly correlated ( Figure 1 ).
| DISCUSSION

Replication of genetic variants identified in BP GWAS in different
populations is necessary to improve generalizability of findings to diverse populations. In particular, replication of findings in samples of populations with lower linkage disequilibrium, notably African populations, usually leads to more refined estimates of positions of causal variants. 18, 35 In this replication study, the first of its kind among East African population, we were able to replicate 8 of the selected Figure 1 ). This is consistent with our previous study 23 which shows that BP loci may have universal effects across studied populations, and further shows that multiethnic samples are critical for the identification, fine mapping and understanding trait variability.
Among the 8 replicated SNPs, rs2004776 near the AGT had the strongest association evidence with BP traits in this study and was replicated for SBP, DBP and HTN. The AGT gene has been implicated in both the pathogenesis of HTN and BP response to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. 36 Multiple consortium-based GWAS have confirmed this SNP-BP trait association in samples derived from population of European and East Asian ancestry. [36] [37] [38] The effect direction of this association in European samples is same to that found in our samples 36 (Table S1 ). Many candidate studies also suggested the variants in AGT are associated with BP traits. 39, 40 Previously, other AGT variants associated with HTN in Caucasians could not be replicated in indigenous Africans. 41 The SNP rs381815 found near the PLEKHA7 gene was replicated for DBP; whereas rs11977526 which is near IGFBP-3 was replicated for DBP and HTN. These 2 variants have consistent association evidence in multiethnic populations such as Europeans, South East
Asians and African-Americans and now in East Africans, suggesting that this association may have a broad role in BP regulation across ethnicities. [42] [43] [44] Post-GWAS evaluation for the mechanistic contribution of PLEKHA7 to BP traits and cardiovascular function has revealed a role in the regulation of ion calcium, nitric oxide bioavailability, and vasculature responsiveness. 45 Zhu et al, using the summary statistics from COGENT African ancestry GWAS, identified rs11977526 as the most significant IGFBP3-related SNP in association with multiple BP traits among SBP, DBP and HTN. 32 IGFBP-3 binds IGF-1 thereby reducing action at the cellular level which subsequently decreases vascular resistance through stimulation of nitric oxide synthesis. 46 The SNPs, rs1458038, rs11725861 and rs11953630, found in the proximity of FGF5, CHIC2 and EBF1, respectively, were significantly associated with PP. In addition, rs11725861 and rs11953630 were significant for all the traits in the combined analysis. These SNPs have showed interethnic replication among diverse ethnicities. 32, 47, 48 More importantly, the 3 variants have been associated with BP responsiveness to beta-blocker and thiazide diuretic monotherapy with among
Caucasians. 49 The SNP rs1458038 near FGF5, for example, was asso- association between rs7726475 and SBP and DBP. 26 The NPR3 gene was reported to be significantly associated with BP traits with another SNP, rs1173771 with same direction, in previous interethnic GWAS in East Asians and Europeans. 25, 51 The difference in effect direction of the SNPs compared to the primary populations associations suggests that the same locus may have varying effects among different ethnic groups. True genetic architectural variation among populations and differences in linkage disequilibrium may be responsible for these differential effect directions although the effect of environmental cannot be completely ruled out. 53 The clinical implications of identified variants are limited by available data on cardiovascular outcomes in populations of African ancestry. However, 3 of the replicated SNPs have showed association While it is clear that many variants display trans-ethnic replication, the finding that our most significant variants have an opposite effect direction to that found in the primary studies calls for further studies to elucidate the effect of these variants on BP traits in the African.
| CONCLUSION
We were able to replicate multiple BP variants identified from previous BP GWAS of Europeans, African-Americans and Eastern Asians or admixture mapping analysis in our Eastern African population, which has not been studied previously. However, we also failed to replicate many variants possibly because of insufficient statistical power of the current sample size. We also observed that some variants have different 
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